‒ Vabysmo achieved its primary endpoint of non-inferiority compared to aflibercept in RVO in the BALATON and COMINO clinical trials – ‒ Vabysmo was generally well tolerated, with a safety profile consistent with previous trials – ‒ Vabysmo is the first and only treatment that targets and inhibits two disease pathways involving Ang-2 and VEGF-A, … [Read more…]
PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today presents its sales performance for the year to date and the third quarter of 2022. Sales summary1 YTD 2022 YTD 2021 % change Q32022 Q32021 % change €m €m Actual CER2 €m €m Actual CER2 Oncology 1,767.2 1,565.4 12.9% 6.9% … [Read more…]
Congratulates Mirum on Positive Topline Phase 3 Data in progressive familial intrahepatic cholestasis (PFIC) CANbridge holds exclusive Greater China license to maralixibat (CAN108) in liver diseases, China trial ongoing in biliary atresia (BA) BEIJING & BURLINGTON, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation in China, committed to the research, development … [Read more…]
MINNETONKA, Minn.–(BUSINESS WIRE)–Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced it has filed its ANDA Application with Paragraph IV Certification on July 20th, 2022 and received a Paragraph IV Acknowledgement Letter and Receipt from FDA on August 31st, 2022. After providing the requisite notice to the NDA holder, the Company reports that … [Read more…]
Multiple extensive studies demonstrate UV Angel Clean Air™ units as an effective solution for healthcare facilities to protect frontline staff, patients, and families GRAND HAVEN, Mich.–(BUSINESS WIRE)–UV Angel, a Michigan-based leading disinfection technology company harnessing the power of UV Light technology (UVGI), advanced optical engineering, and a first-of-its-kind digital software platform, today announced the results … [Read more…]
SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report third quarter 2022 financial results after the close of the U.S. financial markets on Monday, November 7, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO … [Read more…]
PALO ALTO, Calif.–(BUSINESS WIRE)–#diabetes—Tidepool, a medical device company fostering the next generation of diabetes innovation, announced the addition of leading experts in the women’s health and endocrinology space as members of the Tidepool Advisory Council – affirming the organization’s commitment to championing women’s health and diabetes initiatives. Tidepool originally kicked off the Tidepool Period Project … [Read more…]
Corrects the Record Regarding Activist Group’s False and Misleading Statements Highlights Evidence of Group’s Scheme to Have Jorgl Serve as the “Face of the Activist” to Help Them “Get Control” Without Paying a Premium to All Shareholders Group Concealed that Its Campaign Was Orchestrated by One Convicted Felon and Financed by Another Criminal – Until … [Read more…]
OVERLAND PARK, Kan.–(BUSINESS WIRE)–SelectQuote, Inc. (NYSE: SLQT) (the “Company”) today announced that it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) indicating that the Company is no longer in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s common stock was … [Read more…]
TORONTO–(BUSINESS WIRE)–Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (“Greenbrook” or the “Company”), will release its 2022 third quarter operational and financial results after market hours on November 8, 2022. THIRD QUARTER 2022 CONFERENCE CALL DETAILS: Bill Leonard, President and Chief Executive Officer, and Erns Loubser, Chief Financial Officer, will host a conference call at 10:00 … [Read more…]
